comparemela.com

Latest Breaking News On - Efficacy results - Page 8 : comparemela.com

Elixir Medical Corporation: EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)

First head-to-head randomized clinical trial (RCT) of DynamX Bioadaptor compared to Resolute Onyx DES shows statistically significant effectiveness in restoring vessel pulsatility, achieving significantly

United statesErich sandovalGewinn nurMotasim sirhanElixir medical corporationDevelopment of the dynamx bioadaptortheDynamx bioadaptorResolute onyxTarget lesion failureDrug eluting bioadaptorEluting stentClinical safetyEfficacy resultsDevice effectivenessVessel function resultsPlaque stabilization

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Company-sponsored webinar to be announcedCAMBRIDGE, Mass., May 11, 2023 Editas Medicine, Inc. , a clinical stage genome editing company, today announced that a scientific abstract detailing. | May 11, 2023

United statesUnited kingdomBaisong meiRabi hannaHarvard university casDepartment of pediatric hematology oncologyEuropean hematology association congressBroad institute casEuropean hematology associationEditas medicine incBroad instituteHybrid congressSenior vice presidentChief medical officerPresentation detailsPromising preliminary safety

Ocugen Provides Business Update with First Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber. | May 5, 2023

United statesShankar musunuriOcugen incExchange commissionHead of communicationsConference callWebcast todayPositive preliminary safetyEfficacy resultsRetinitis pigmentosaLeber congenital amaurosisOrphan drug designationAssociated retinopathies including stargardtCone rod dystrophyMultiple proposalsFederal funding

StreetInsider com - Corporate News

StreetInsider com - Corporate News
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongStock exchange of hong kongAminozyme pharma incAmlufax holdingFreestyle librePresent recently announced preliminary dataOngoing phaseAnnounces pricingRegistered direct offeringCommon stockAnnounces positive preliminary safetyEfficacy resultsPays off senior secured convertibleMain boardStock exchangeEnters into cooperation agreement

Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduc

Destiny Pharma plc("Destiny Pharma" or "the Company") Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology  Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients   Brighton, United Kingdo.

Brighton and hoveUnited kingdomData safety monitoring committeeDivision of infectious diseasesOhio state universityDestiny pharmaInfection controlHospital epidemiologyJulie manginoProfessor emeritusInfectious diseasesExeporfinium chlorideNasal gel dosedSurgery significantly reduced staphylococcusNasal carriageCardiac surgery patients

vimarsana © 2020. All Rights Reserved.